WEST LAFAYETTE, Ind.--(BUSINESS WIRE)-- #Biotech--Eradivir, Inc., a clinical-stage biotech company developing antibody-recruiting small molecules to treat disease, today announced the dosing of the first patient with influenza in a Phase 2 study evaluating EV25 in adults with naturally occurring influenza infection in Bangladesh. The safety lead-in portion of the study was completed last month, with EV25 being well tolerated across all cohorts. The study marks the first evaluation of EV25 in pat